Real world outcomes in patients with neuroendocrine tumor receiving peptide receptor radionucleotide therapy.

Stijn HentzenKathan MehtaRaed Moh'd Taiseer Al-RajabiAnwaar SaeedJoaquina Celebre BarandaStephen K WilliamsonWeijing SunAnup Kasi Loknath Kumar

Published in: Exploration of targeted anti-tumor therapy (2023)

This real world outcomes analysis of NETs treated with Lu-177 shows improved PR when compared to the initial clinical trials and is promising for patients. In addition, patients with non-functional tumors were found to have a statistically significant improved response rate which has not been described in the literature before. If these study findings are validated in a larger cohort they may guide patient selection for Lu-177 therapy in the future.

Keyphrases

clinical trial
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
systematic review
peritoneal dialysis
case report
skeletal muscle
patient reported outcomes
bone marrow
insulin resistance
study protocol